Paper Details

  1. Home
  2. Paper Details

Levomilnacipran extended-release: a review of its use in adult patients with major depressive disorder.

Author: ScottLesley J

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

This article summarizes the clinical use of oral levomilnacipran extended-release (ER) in adults with major depressive disorder (MDD). Levomilnacipran ER is a serotonin norepinephrine reuptake inhibitor that has been shown to be effective and generally well-tolerated in treating MDD.
Paper Details　
Original Abstract of the Article :
Oral levomilnacipran extended-release (ER) [Fetzima™], the more active enantiomer of milnacipran, is the most recent serotonin norepinephrine reuptake inhibitor to be approved in the USA for the treatment of adults with major depressive disorder (MDD). MDD is characterized by depression and impairme...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1007/s40263-014-0203-1

データ提供：米国国立医学図書館（NLM）

Levomilnacipran Extended-Release: A New Option for Major Depressive Disorder

Major depressive disorder (MDD) is a serious mental health condition that can significantly impact a person's life. This study explores the effectiveness and safety of levomilnacipran extended-release (ER), a new medication for treating MDD. It's like discovering a new type of plant in the desert that can help nourish the mind and spirit.

Effective Treatment with Levomilnacipran ER

The study found that levomilnacipran ER was effective in treating MDD, leading to significant improvements in depressive symptoms and functional outcomes. This is like finding a wellspring of relief in the desert of depression, providing much-needed solace and support. The medication was generally well-tolerated, with no new safety signals detected. This is like discovering a safe haven in the desert, ensuring that the treatment is effective and safe.

A New Oasis for MDD Treatment

This study provides a promising new treatment option for individuals struggling with MDD. It's like finding a new oasis in the desert of mental health, offering hope and healing for those who need it most. Further research is needed to fully understand the long-term safety and efficacy of levomilnacipran ER, but this study provides a strong foundation for future exploration.

Dr.Camel's Conclusion

This study sheds light on the potential of levomilnacipran ER as a new and effective treatment option for MDD. It's like finding a new and refreshing oasis in the desert of mental health, offering hope and healing to those who need it most. This research is a testament to the ongoing efforts in medicine to alleviate the suffering of individuals struggling with mental health conditions.

Date :
  1. Date Completed 2015-06-25
  2. Date Revised 2022-12-07
Further Info :

Pubmed ID

25270036

DOI: Digital Object Identifier

10.1007/s40263-014-0203-1

Related Literature

Article Analysis
・Effects of levomilnacipran
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.